Table 1.
Characteristics of patients with primary HCC in the training cohort and validation cohort.
| Characteristics | Training cohort | Validation cohort | p value |
|---|---|---|---|
| Age, year, median, (range) | 54.0 (21.0-92.0) | 54.5 (22.0-81.0) | 0.647 |
| Gender (female/male), % | 83/437 (16 /84) | 27/167 (13.9 /86.1) | 0.501 |
| Cirrhosis (yes/no), % | 389/131 (74.8 /25.2) | 145/49 (74.7 /25.3) | 0.986 |
| ALT, U/L, median (range) | 42.6 (3.0-615.0) | 43.6 (9.0-915.0) | 0.833 |
| AFP, ng/ml, (≤400/>400), % | 382/138 (73.5 /26.5) | 138/56 (71.1 /28.9) | 0.534 |
| HBsAg (positive/negative), % | 405/115 (77.9 /22.1) | 153/41 (78.9 /21.1) | 0.778 |
| GGT, U/L, (≤50/>50), % | 266/254 (51.2 /48.8) | 88/106 (45.4 /54.6) | 0.168 |
| Tumor size, cm, (≤5.0/>5.0), % | 337/183 (64.8 /35.2) | 121/73 (62.4 /37.6) | 0.546 |
| Tumor number (single/multiple), % | 446/74 (85.8 /14.2) | 164/30 (84.5 /15.5) | 0.678 |
| Microvascular invasion (yes/no), % | 159/361 (30.6 /69.4) | 52/142 (26.8 /73.2) | 0.326 |
| Differentiation (poor/moderate/well), % | 121/226/173 (23.2/43.5/33.3) | 45/92/57 (23.2/47.4 /29.4) | 0.323 |
| Tumor capsule (yes/no), % | 194/326 (37.3 /62.7) | 59/135 (30.4 /69.6) | 0.087 |
| ALBI (Ⅰ/Ⅱ) , % | 377/143 (72.5 /27.5) | 146/48 (75.3 /24.7) | 0.459 |
| Child-Pugh grade (A/B), % | 518/2 (99.6 /0.4) | 193/1 (99.5 /0.5) | 1.000 |
| AJCC stage (Ⅰ/Ⅱ/Ⅲ) , % | 349/112/59 (67.1 /21.5 /11.3) | 130/42/22 (67.0 /21.6 /11.3) | 0.986 |
| BCLC stage (1/2/3), % | 324/160/36 (62.3 /30.8 /6.9) | 115/69/10 (59.3 /35.6 /5.2) | 0.807 |
| CLIP stage (0/1/2/3/4), % | 292/145/45/32/6 (56.2 /27.9/8.7 /6.2 /1.2) | 105/57/17/13/2 (54.1 /29.4 /8.8 /6.7 /1.0) | 0.720 |
ALT, Alanine aminotransferase; AFP, Alkaline phosphatase; HBsAg, Hepatitis B virus surface antigen; GGT, Gamma-glutamyl transpeptidase; ALBI, Albumin-bilirubin; AJCC, American Joint Committee on Cancer, BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program.